Molecular docking demonstration of the liquorice chemical molecules on the protease and ace2 of covid-19 virus
Current Enzyme Inhibition
; 17(2):98-110, 2021.
Article
in English
| EMBASE | ID: covidwho-1526728
ABSTRACT
Background:
COVID-19 has spread rapidly in many countries of the world and poses a serious threat to global public health, yet no specific drug has been identified or currently available for its treatment. Since it may take years to design a drug for its treatment, the shortest and most effective way now is to screen the available drugs or active substances by molecular docking methods.Objective:
The aim of this study is to investigate the potential for use in COVID-19 treatment by investigating the inhibitory effects of Glycyrrhiza glabra, main active ingredients on COVID-19, main protease (SARS-CoV-2,), SARS-CoV-2-ACE2 Complex and ACE-2 by molecular docking method, which are known to have antiviral effects on SARS-CoV. Material andMethods:
Molecular docking was performed by using Autodock 4.2 to analyse the proba-bility of docking. Several compounds extracted from the root of the licorice plant (glycyrrhizic acid, glabridin, 6-azauridine, pyrazofurin and mycophenolic acid) were docked to inhibit COVID-19 Mpro and docking results were analysed by Autodock 4.2 and Biovia Discovery Studio Visualizer 2020. The evalu-ation was based on the docking score (binding energies) calculated by Autodock 4.2. Nelfinavir was used as standards for comparison.Results:
As a result of the study, the compounds of Glabridin in COVID-19 main protease (6LU7), ACE-2 (1R4L) and SARS-CoV-2,-ACE2 Complex (6LZG) have very low binding energy (-8.75 to-7.64) and low potential to inhibition constant has been found.Conclusion:
These results suggest that Glabridin appeared to have the best potential to act as a COVID-19 Mpro inhibitor. However, further research is necessary to investigate their potential medicinal use.
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Current Enzyme Inhibition
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS